[(3)H]-(3-bromo-6-(1H-pyrazol-4-yl)-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)(3-(thiophen-2-yl)pyrrolidin-1-yl)methanone | 1379660-21-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: [(3)H]-(3-bromo-6-(1H-pyrazol-4-yl)-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)(3-(thiophen-2-yl)pyrrolidin-1-yl)methanone
• 英文别名: [3-bromo-6-(1H-pyrazol-4-yl)-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]-(3-thiophen-2-yl-3,4-ditritiopyrrolidin-1-yl)methanone
• CAS: 1379660-21-5
• 化学式: C₂₀H₁₅BrF₃N₅OS
• 分子量: 514.321
• InChiKey: PCFYBIHUFQUGCS-QJMNVCFXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  94.5
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  3-(thiophen-2-yl)-2,5-dihydro-pyrrole-1-carboxylic acid tert-butyl ester 在 超重氢 、 palladium 10% on activated carbon 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、50.67 kPa 条件下， 反应 1.5h， 生成 [(3)H]-(3-bromo-6-(1H-pyrazol-4-yl)-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)(3-(thiophen-2-yl)pyrrolidin-1-yl)methanone
  参考文献：
  名称：

  Imidazo[1,2-a]pyridines That Directly Interact with Hepatitis C NS4B: Initial Preclinical Characterization

  摘要：

  A series of imidazo[1,2-a]pyridines which directly bind to HCV Non-Structural Protein 4B (NS4B) is described. This series demonstrates potent in vitro inhibition of HCV replication (EC50 < 10 nM), direct binding to purified NS4B protein (IC50 < 20 nM), and an HCV resistance pattern associated with NS4B (H94N/R, V105L/M, F98L) that are unique among reported HCV clinical assets, suggestive of the potential for additive or synergistic combination with other small molecule inhibitors of HCV replication.

  DOI：

  10.1021/ml300090x

文献信息

• Imidazo[1,2-<i>a</i>]pyridines That Directly Interact with Hepatitis C NS4B: Initial Preclinical Characterization
  作者：J. Brad Shotwell、Subramanian Baskaran、Pek Chong、Katrina L. Creech、Renae M. Crosby、Hamilton Dickson、Jing Fang、Dulce Garrido、Amanda Mathis、Jack Maung、Derek J. Parks、Jeffrey J. Pouliot、Daniel J. Price、Roopa Rai、John W. Seal、Uli Schmitz、Vincent W. F. Tai、Michael Thomson、Mi Xie、Zhiping Z. Xiong、Andrew J. Peat

  DOI：10.1021/ml300090x

  日期：2012.7.12

  A series of imidazo[1,2-a]pyridines which directly bind to HCV Non-Structural Protein 4B (NS4B) is described. This series demonstrates potent in vitro inhibition of HCV replication (EC50 < 10 nM), direct binding to purified NS4B protein (IC50 < 20 nM), and an HCV resistance pattern associated with NS4B (H94N/R, V105L/M, F98L) that are unique among reported HCV clinical assets, suggestive of the potential for additive or synergistic combination with other small molecule inhibitors of HCV replication.